Documentation of SS for LAI [Design Issues]

posted by Achievwin – US, 2023-02-06 14:40 (46 d 14:22 ago) – Posting: # 23440
Views: 520


Long Acting Injectable products BE guidance require steady state documentation before dosing patients for PK sampling.

My basic questions are

1) how do you document SS (any simple and accepted statistical test?)
2) do you analyze pre-dose samples before the PK-dosing and decide on to dose or add another dosing prior to the PK/BE sampling? or let the study complete and drop the subject (for that period) when the subject fail to meet the SS criteria?

Analyzing pre-dose samples prior to the planned PK dosing in patient studies poses operational challenges and evaluating SS after the entire study completion carries risk of unknown N of patients dropped for SS reasons.

Your guidance is much appreciated.

Complete thread:

UA Flag
 Admin contact
22,550 posts in 4,724 threads, 1,606 registered users;
11 visitors (0 registered, 11 guests [including 7 identified bots]).
Forum time: 05:03 CET (Europe/Vienna)

If there is an exception to any rule,
and if it can be proved by observation,
that rule is wrong.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz